NASDAQ:MLTX MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis $12.51 -0.67 (-5.08%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$12.62 +0.11 (+0.84%) As of 09/11/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MLTX alerts:Sign Up Key Stats Today's Range$12.47▼$13.5550-Day Range$12.51▼$20.4152-Week Range$5.95▼$62.75Volume2.38 million shsAverage Volume1.07 million shsMarket Capitalization$1.06 billionP/E RatioN/ADividend YieldN/APrice Target$24.57Consensus RatingHold Company Overview MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for inflammatory and immunologic diseases. The company’s approach is based on Nanobody technology, which is designed to create targeted therapies with potential advantages in tissue penetration and biological activity. MoonLake’s lead product candidate is sonelokimab, a trivalent Nanobody designed to selectively inhibit interleukin-17A and interleukin-17F, two cytokines involved in inflammatory disease. The company is evaluating sonelokimab in conditions including hidradenitis suppurativa, psoriatic arthritis and axial spondyloarthritis, with the goal of addressing significant unmet medical needs in these and potentially other inflammatory disorders. MoonLake Immunotherapeutics is headquartered in Zug, Switzerland, and conducts clinical development activities internationally. The company became publicly traded on the Nasdaq following a business combination with Helix Acquisition Corp. in 2022. Its management team is led by Chief Executive Officer Jorge Santos da Silva.AI Generated. May Contain Errors. Read More MoonLake Immunotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreMLTX MarketRank™: MoonLake Immunotherapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 693rd out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingMoonLake Immunotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.41, and is based on no strong buy ratings, 10 buy ratings, 4 hold ratings, and 3 sell ratings.Upside PotentialMoonLake Immunotherapeutics has a consensus price target of $24.57, representing about 96.4% upside from its current price of $12.51.Amount of Analyst CoverageMoonLake Immunotherapeutics has only been the subject of 3 research reports in the past 90 days.Read more about MoonLake Immunotherapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($3.34) to ($3.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MoonLake Immunotherapeutics is -3.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MoonLake Immunotherapeutics is -3.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoonLake Immunotherapeutics has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about MoonLake Immunotherapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.37% of the float of MoonLake Immunotherapeutics has been sold short.Short Interest Ratio / Days to CoverMoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 6.68.Change versus previous monthShort interest in MoonLake Immunotherapeutics has recently increased by 4.77%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMoonLake Immunotherapeutics does not currently pay a dividend.Dividend GrowthMoonLake Immunotherapeutics does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment0.32 News SentimentMoonLake Immunotherapeutics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for MoonLake Immunotherapeutics this week, compared to 10 articles on an average week.Search InterestOnly 4 people have searched for MLTX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added MoonLake Immunotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MoonLake Immunotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,820,071.00 in company stock.Percentage Held by Insiders10.40% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MoonLake Immunotherapeutics' insider trading history. Receive MLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MLTX Stock News HeadlinesMLTX stock on track for worst week since last fall as FDA filing date for skin disease drug draws nearSeptember 11 at 6:09 PM | msn.comMoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical SupremacySeptember 8, 2026 | seekingalpha.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 13 at 1:00 AM | Porter & Company (Ad)MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of "Hold" by AnalystsSeptember 4, 2026 | americanbankingnews.comMoonLake Immunotherapeutics (MLTX)August 23, 2026 | finance.yahoo.comMoonLake’s psoriatic arthritis drug shows promise in phase 3 trial – retail shrugs off premarket slide, says ‘pipeline is intact’August 11, 2026 | msn.comMoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical GoalsAugust 10, 2026 | finance.yahoo.comMoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical ...August 10, 2026 | markets.businessinsider.comSee More Headlines MLTX Stock Analysis - Frequently Asked Questions How have MLTX shares performed this year? MoonLake Immunotherapeutics' stock was trading at $13.18 on January 1st, 2026. Since then, MLTX stock has decreased by 5.1% and is now trading at $12.51. How were MoonLake Immunotherapeutics' earnings last quarter? MoonLake Immunotherapeutics (NASDAQ:MLTX) issued its earnings results on Monday, August, 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.07. When did MoonLake Immunotherapeutics IPO? MoonLake Immunotherapeutics (MLTX) raised $100 million in an initial public offering on Tuesday, October 20th 2020. The company issued 10,000,000 shares at $10.00 per share. Who are MoonLake Immunotherapeutics' major shareholders? Top institutional shareholders of MoonLake Immunotherapeutics include California State Teachers Retirement System (0.87%), Engineers Gate Manager LP (0.13%), Squarepoint Ops LLC (0.10%) and Headlands Technologies LLC (0.07%). Insiders that own company stock include Da Silva Jorge Santos, Kristian Reich, Bvf Partners L P/Il, Matthias Bodenstedt and Simon Sturge. View institutional ownership trends. How do I buy shares of MoonLake Immunotherapeutics? Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MoonLake Immunotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that MoonLake Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Disc Medicine (IRON), e.l.f. Beauty (ELF), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Arista Networks (ANET). Company Calendar Last Earnings8/10/2026Today9/13/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, MLTX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MLTX CIK1821586 Webwww.moonlaketx.com Phone41-41-510-8022FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Price Target for MoonLake Immunotherapeutics$24.57 High Price Target$50.00 Low Price Target$8.00 Potential Upside/Downside+96.4%Consensus RatingHold Rating Score (0-4)2.41 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($3.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$227.32 million Net MarginsN/A Pretax MarginN/A Return on Equity-82.53% Return on Assets-58.17% Debt Debt-to-Equity Ratio0.23 Current Ratio12.56 Quick Ratio12.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.27 per share Price / Book2.93Miscellaneous Outstanding Shares85,110,000Free Float76,256,000Market Cap$1.06 billion OptionableOptionable Beta1.04 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:MLTX) was last updated on 9/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
